指南与共识消化系统肿瘤支持与姑息治疗

食管小细胞癌多学科诊疗专家共识(2026版)

[Expert consensus on multidisciplinary diagnosis and treatment of small cell carcinoma of the esophagus (2026 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

食管小细胞癌(SCEC)是少见的高度侵袭性神经内分泌肿瘤,预后差,诊断依赖胃镜活检病理及免疫组化。共识推荐超声胃镜、增强CT或PET-CT、颅脑MRI精确分期,联合AJCC-TNM与VALSG分期指导治疗,强调化疗、放疗及手术的多学科综合模式。局限期推荐化疗联合局部治疗,广泛期以全身化疗为主,首选依托泊苷联合铂类方案。

要点

  • 诊断依赖胃镜活检病理及免疫组化,推荐超声胃镜、增强CT或PET-CT、颅脑MRI精确分期。
  • 局限期推荐化疗联合局部治疗,可手术者行根治性放化疗或围手术期治疗联合根治性手术。
  • 广泛期以全身化疗为主,首选依托泊苷联合铂类方案,残留病灶可追加局部治疗。

核心结论

  • 共识旨在推进SCEC诊疗规范化,通过多学科协作改善患者生活质量和长期生存。

研究设计与样本

  • 本共识为食管小细胞癌多学科诊疗专家共识(2026版),由中华肿瘤杂志发布,具体制定机构与方法原文未详述。

主要发现

  • SCEC是少见的高度侵袭性神经内分泌肿瘤,预后差,临床表现缺乏特异性。
  • 诊断依赖胃镜活检病理及免疫组化检查。
  • 推荐使用超声胃镜、增强CT或PET-CT、颅脑MRI进行精确分期。
  • 建议联合应用AJCC-TNM分期系统和VALSG分期系统指导治疗。
  • 免疫治疗尚缺乏高级别循证医学证据,推荐开展相关临床研究。

关键数值与推荐

  • 局限期患者推荐化疗联合局部治疗(手术或放疗)。
  • 可手术患者建议行根治性放化疗或围手术期治疗联合根治性手术,不可手术患者行根治性放化疗。
  • 广泛期患者以全身化疗为主,化疗首选依托泊苷联合铂类方案。
  • 全身治疗有效的情况下,对残留病灶可追加局部治疗。
  • 有症状的转移灶建议姑息减症治疗。

临床怎么用

  • 临床应采用多学科综合模式,整合化疗、放疗及手术进行诊疗决策。
  • 按分期分层治疗:局限期化疗联合局部治疗,广泛期以全身化疗为主。
  • 广泛期化疗首选依托泊苷联合铂类方案,全身治疗有效后残留病灶可追加局部治疗。
  • 有症状的转移灶建议姑息减症治疗。
  • 免疫治疗应限于临床研究框架内开展。

局限性

  • 免疫治疗尚缺乏高级别循证医学证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Small cell carcinoma of the esophagus (SCEC) is a rare and highly aggressive neuroendocrine tumor with poor prognosis. Its clinical manifestations lack specificity, and diagnosis relies on gastroscopic biopsy pathology and immunohistochemistry. The use of ultrasonic gastroscope, enhanced CT or positron emission tomography-computed tomography (PET-CT), and brain MRI is recommended for accurate staging. The American Joint Committee on Cancer-tumor, node, metastasis (AJCC-TNM) staging system and the Veterans Administration Lung Study Group (VALSG) staging systems are adopted to guide the treatment. The treatment emphasizes a multidisciplinary comprehensive mode incorporating chemotherapy, radiotherapy and surgery. For patients with limited-stage disease, chemotherapy combined with local treatment (surgery or radiotherapy) is recommended. For operable patients, radical chemoradiotherapy or perioperative treatment followed by radical surgery is recommended, while patients with inoperable disease should receive radical chemoradiotherapy. For patients with extensive-stage disease, systemic chemotherapy is the mainstay, while etoposide plus platinum as the preferred regimen. If systemic treatment is effective, additional local treatment may be administered for residual lesions. Palliative treatment is recommended for symptomatic metastases. There is currently a lack of high-level evidence-based medical evidence for immunotherapy, and relevant clinical trials are recommended. This consensus aims to promote the standardized diagnosis and treatment of SCEC and to improve patients' quality of life and long-term survival through multidisciplinary collaboration. 食管小细胞癌(SCEC)是一种少见的高度侵袭性神经内分泌肿瘤,预后差,临床表现缺乏特异性,诊断依赖胃镜活检病理及免疫组化检查。推荐使用超声胃镜、增强CT或正电子发射计算机断层扫描、颅脑MRI进行精确分期,建议联合应用美国癌症联合委员会TNM分期系统和美国退伍军人肺癌研究组分期系统指导治疗。治疗强调化疗、放疗及手术等的多学科综合模式。局限期患者推荐化疗联合局部治疗(手术或放疗)。可手术患者建议行根治性放化疗或围手术期治疗联合根治性手术,不可手术患者行根治性放化疗。广泛期患者以全身化疗为主,化疗首选依托泊苷联合铂类方案。全身治疗有效的情况下,对残留病灶可追加局部治疗。有症状的转移灶建议姑息减症治疗。免疫治疗尚缺乏高级别循证医学证据,推荐开展相关临床研究。共识旨在推进SCEC诊疗规范化,通过多学科协作改善患者生活质量和长期生存。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Expert consensus on multidisciplinary diagnosis and treatment of small cell carcinoma of the esophagus (2026 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 41813228. doi:10.3760/cma.j.cn112152-20251114-00570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。